ENGLEWOOD, Colo., Sept. 3, 2020 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced order growth for July and August 2020.
Aggregate orders in July and August were 83% above the prior year July and August aggregate and well above the 37% growth in the second quarter of 2020.
Thomas Sandgaard, CEO of Zynex said: "In June, as many cities re-opened their doors for business, we have seen consistent order growth and it has continued in the third quarter as we posted 83% year-over-year order growth in July and August as we move closer to pre-COVID-19 sales rep productivity levels. We don't typically give order growth updates on a monthly basis but we thought it was important to share our progress as business returns to normal. Our continued order growth during this pandemic shows the strength of relationships our sales force has with many prescribers and the need for them to prescribe non-opioid, non-addictive prescription strength solutions for their patients in pain."
The Company's full year 2020 revenue estimate is between $80 and $85 million whichis approximately 76% to 87% above last year's full year revenue of $45.5 million.
2020 full year estimated adjusted EBITDA is $15.0 to $18.0 million.
Our prescription-strength NexWave device is a healthy alternative to prescribing opioids as the first line of defense when treating pain. We continue to add additional sales reps in territories throughout the US that we have not covered previously.
We continue to advocate for pain patients, and for physicians to prescribe our NexWave technology as the first line of defense in treating chronic and acute pain without side effects. We are dedicated to promoting our technology in an effort to remove patient addiction and other side effects from prescription opioids."